A randomised, open, controlled pilot study to investigate the efficacy and safety of Buparid/PARI SINUS versus Budes Nasal Spray in the therapy of Chronic Rhinosinusitis (CRS) with polyposis nasi in adult patients
Phase of Trial: Phase III
Latest Information Update: 28 Jul 2018
Price : $35 *
At a glance
- Drugs Budesonide (Primary)
- Indications Rhinosinusitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors PARI Pharma GmbH
- 25 Apr 2018 Planned primary completion date changed from 1 May 2018 to 1 Dec 2018.
- 25 Apr 2018 Planned End Date changed from 1 Nov 2018 to 1 May 2019.
- 12 Dec 2017 Planned End Date changed from 1 Mar 2018 to 1 Nov 2018.